Brooks Laboratories Limited board approved the demerger of its Manufacturing Business into Abridge Speciality Limited on October 14, 2026. The demerged unit represents 96.66% of the company's FY26 turnover, signaling a major structural shift.

The scheme, filed under Regulation 30 of SEBI Listing Regulations, involves transferring manufacturing operations at the Baddi facility, including exports, loan-licensing, and contract manufacturing, to the wholly owned subsidiary. The arrangement is subject to approvals from NCLT, SEBI, stock exchanges, and shareholders. Upon effectiveness, Abridge Speciality Limited will be renamed Brooks Laboratories Limited, while the existing listed entity will be renamed Xuri Lifesciences Limited.

Share Entitlement and Structure

The restructuring follows a 1:1 share entitlement ratio. For every one equity share held in the current entity, shareholders will receive one equity share in the resulting company. There is no cash consideration involved. The shareholding pattern of the Resulting Company will mirror that of the Demerged Company, with promoter group holding 52.62% and public shareholders holding 47.38% post-scheme.

Strategic Rationale

The company cited focused management and accountability as primary drivers for the split. By separating the manufacturing operations from trading activities, each platform can pursue independent growth strategies with dedicated management teams. The move aims to align ownership with promoter groups associated with specific businesses, facilitating clearer governance and operational clarity.

The presentation indicates that both entities will have expected capital availability of approximately ₹50 crore for strategic growth and expansion. This capital allocation suggests a balanced approach to funding future initiatives for both the manufacturing and trading arms.

What the Numbers Show

The demerger effectively transfers nearly all revenue-generating operations to the new entity. With the Manufacturing Business accounting for 96.66% of FY26 turnover, the residual trading business retains a minimal share of the top line. This concentration implies that the value creation narrative hinges almost entirely on the performance of the manufacturing unit under the new banner. The retained trading business appears to be a minor component relative to the scale of the manufacturing operations being spun off.

Timeline and Listing

The scheme is projected to take about 16 months from filing to listing. Key stages include board and exchange approvals (months 1–6), NCLT first motion and regulatory NOCs (months 6–10), NCLT sanction (months 10–13), and final allotment and listing (months 13–16). The Resulting Company will seek listing on BSE and NSE upon completion of these steps.

Brooks Laboratories Limited has accepted the resignation of Ms. Krutika Rane as Company Secretary and Compliance Officer. Her departure is effective from the close of business on October 9, 2026.

Ms. Rane cited an alternate career opportunity outside the organization as the reason for her exit. The company disclosed this development in a filing dated September 16, 2026.

Regulatory Compliance

The intimation was issued in accordance with Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Brooks Laboratories informed both the BSE Limited and the National Stock Exchange of India Ltd regarding the change in Key Managerial Personnel.

Resignation Details

Ms. Rane submitted her resignation letter to the Board of Directors on September 16, 2026. In her letter, she thanked the board for their support during her tenure and requested the necessary filings with the Registrar of Companies and stock exchanges to effectuate the resignation.

Bhushan Singh Rana, Whole-Time Director, signed the disclosure on behalf of the company.